美国成年癌症幸存者的主观与客观听力损失
该横断面研究基于美国国家健康与营养调查(NHANES)2011-2012、2015-2016及2017年至2020年3月疫情前三个周期数据,纳入20至80岁完成听力问卷和听力检测的9337名成人(加权n=90098441,51.2%为女性),其中10.3%为癌症幸存者。癌症幸存者烦恼性听力损失、言语频率听力损失和高频听力损失患病率均高于一般人群,而耳鸣无显著差异。两个主观听力问题筛查真实听力损失的年龄和性别调整曲线下面积分别为0.88(言语频率)和0.90(高频)。
要点
- 癌症幸存者烦恼性听力损失、言语频率和高频听力损失患病率均高于一般人群。
- 耳鸣在癌症幸存者与一般人群间无显著差异。
- 两个主观听力问题可较准确识别真实听力损失,或可提供简单高效的筛查工具。
核心结论
- 研究发现癌症幸存者听力损失患病率显著高于一般人群。
- 两个主观听力问题或可准确识别真实听力损失,为医疗专业人员提供简单高效的筛查工具。
- 应教育和鼓励癌症幸存者及其家属讨论听力问题,医疗专业人员应提高意识并在发现听力损失时提供早期筛查和及时转诊。
研究设计与样本
- 横断面设计,选取美国国家健康与营养调查(NHANES)2011-2012、2015-2016及2017年至2020年3月疫情前调查周期中20至80岁完成听力检测并回答听力问卷的成人。
- 数据分析时间为2022年8月13日至2023年7月26日。
- 共纳入9337名参与者(加权n=90098441;51.2%为女性),其中10.3%为癌症幸存者。
主要发现
- 与一般人群相比,癌症幸存者烦恼性听力损失的调整比值比(AOR)为1.43(95%CI 1.11-1.84)。
- 与一般人群相比,癌症幸存者耳鸣的AOR为1.28(95%CI 0.94-1.74)。
- 与一般人群相比,癌症幸存者言语频率听力损失的AOR为1.43(95%CI 1.11-1.85)。
- 与一般人群相比,癌症幸存者高频听力损失的AOR为1.74(95%CI 1.29-2.34)。
- 使用主观听力工具(询问是否有烦恼性听力和/或耳鸣)筛查听力损失时,检测言语频率听力损失的年龄和性别调整曲线下面积为0.88,检测高频听力损失为0.90。
关键数值与推荐
- 主观听力损失定义为烦恼性听力和耳鸣;客观听力损失定义为听力检测的言语频率听力损失和高频听力损失。
- 使用χ2检验和多因素调整逻辑回归模型比较癌症幸存者与一般人群的听力损失。
- 采用年龄和性别调整的逻辑回归估计曲线下面积,以评估主观听力问题筛查客观听力损失的性能。
临床怎么用
- 癌症幸存者及其家属应接受教育并鼓励讨论听力问题。
- 医疗专业人员应促进提高意识,并在发现听力损失时提供早期筛查和及时转诊。
- 两个主观听力问题或可作为简单高效的筛查工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cancer survivors are at a higher risk of developing hearing loss (HL) due to older age, chemotherapy, and radiotherapy. However, the prevalence of HL among US cancer survivors remains unknown. Additionally, there is a lack of uniform HL screening guidelines for this enlarging population. OBJECTIVE: To estimate the prevalence of subjective HL and objective HL by audiometry test among cancer survivors and compare them with the general population as well as to assess the performance of subjective HL questions in detecting true (ie, audiometry-confirmed) HL. DESIGN, SETTING, AND PARTICIPANTS: In a cross-sectional design, adults between ages 20 and 80 years who had audiometry testing and responded to a hearing questionnaire from the National Health and Nutrition Examination Survey (2011-2012, 2015-2016, and 2017 to March 2020 prepandemic survey cycles) were selected. Data analysis was conducted from August 13, 2022, to July 26, 2023. MAIN OUTCOMES AND MEASURES: The weighted prevalence of subjective HL (troublesome hearing and tinnitus) and objective HL (speech-frequency HL and high-frequency HL) by audiometry were calculated. Analyses with χ2 testing and multiadjusted logistic regression models were used to compare HL between cancer survivors and the general population. To evaluate the performance of subjective HL questions as a tool to screen for objective HL by audiometry, areas under the curve were estimated using age- and gender-adjusted logistic regression. RESULTS: Among the total 9337 participants (weighted n = 90 098 441; 51.2% women), 10.3% were cancer survivors. Compared with the general population, cancer survivors had a higher prevalence of troublesome hearing (adjusted odds ratio [AOR], 1.43; 95% CI, 1.11-1.84), tinnitus (AOR, 1.28; 95% CI, 0.94-1.74), speech-frequency HL (AOR, 1.43; 95% CI, 1.11-1.85), and high-frequency HL (AOR, 1.74; 95% CI, 1.29-2.34). When using the subjective HL tool and questioning regarding whether the participants were having troublesome hearing and/or tinnitus in screening for HL, the age- and gender-adjusted area under the curve was 0.88 in detecting speech-frequency HL and 0.90 in detecting high-frequency HL. CONCLUSION AND RELEVANCE: The findings of this study suggest that cancer survivors have a significantly higher prevalence of HL than the general population. Two subjective HL questions could potentially accurately identify those who have true HL and provide a simple and efficient screening tool for health care professionals. Cancer survivors and their families should be educated and encouraged to discuss hearing concerns, and health care professionals should facilitate raising awareness and provide early screening and timely referral when HL is identified.
引用
- Wang Q, Jiang C, Wen C, et al. Subjective and Objective Hearing Loss Among US Adult Cancer Survivors. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 37796484. doi:10.1001/jamaoto.2023.2941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。